Hope you are doing well and enjoying the run up in the stocks.
Well, considering the fall of Mar’20 and the gloom and doom all around, the run up has been truly exceptional with the portfolios moving up by 40% (since March lows) and some individual stocks up more than 50-100% and even more.
Luckily for us as well, a lot of stocks have seen a great run up and helping us outperform benchmark indices by a wide margin.
So, without further ado, we would like to share with you our initiation report on Suven Pharmaceuticals/Suven Lifesciences.
Just a small background:
In May’17, when we initiated the report on Suven Life around 175 odd levels, there was no Suven Pharma then.
However, subsequently in Jan’20, Suven Life got demerged into Suven life and Suven Pharma and we as shareholders of Suven Life got the same number of shares of Suven Pharma.
We closed Suven Life around 50 odd levels while still holding on to Suven Pharmaceuticals which is now quoting around 475-480.
So, from 175 the stock has delivered 200% return.
New Member/Returning Member
Recently we released our New Investment report for Premium Members. It’s a leading cash rich company with dividend yield of more than 15%. It has assets worth replacement cost of Rs 23,000 crore while the company is available at around Rs 3,000 crore (net of cash)
Get access to latest Stock Reports, Special Situation Reports (including Jun’20) and Model Sheet in Premium Memberships
However, the returns have not been instant. We initiated the stock when no one was interested in the Pharma space and as a result, we got a good company at good valuations.
It’s now when the Pharma space is again back in fancy, we are getting a good price for our investment.
Our detailed initiation report can be accessed below:
For other stock reports – LINK
Disclosure: The above note is for educational purpose and not an investment advice. I have personal investment in Suven Pharmaceuticals and the stock is also part of our Model sheet. I have not traded in the stock in the last 30 days.
Research Analyst Details
Name: Ekansh Mittal Email Id: [email protected] Ph: +91 727 5050062
Analyst ownership of the stock: In Suven Pharmaceuticals
Details of Associates: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to retail clients on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision.
A graph of daily closing prices of securities is available at www.bseindia.com (Choose a company from the list on the browser and select the “three years” period in the price chart.
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Disclosure (SEBI RA Regulations)
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – Yes, investment in Suven Pharmaceuticals
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No